Abstract:
Hemocellular Therapeutics, expected to produce the first platelet-based therapeutic available to doctors for the immediate treatment of active bleeding, has established an exclusive licensing agreement with UNC-Chapel Hill and East Carolina University. Key technology developed by researchers at the two universities was central to the development by Hemocellular of a plan to create lyophilized, or \"freeze-dried\" human platelets. The licensing agreement provides for both universities to receive equity in Hemocellular and to share in royalties on the sale of the products.